Atomax-UK brings over 40 years of specialised experience in successfully delivering projects within the pharmaceutical industry, navigating global competition and stringent regulatory landscapes. Our diverse client base includes primary and secondary pharmaceutical manufacturers, specialised equipment suppliers, and medical device experts. We collaborate closely with GMP production facilities, research institutions, and expansive life sciences campuses.
With a deep understanding of regulatory requirements and industry-specific safety standards, Atomax-UK ensures exceptional quality and safety throughout every project phase. We provide comprehensive mechanical, electrical, and instrumentation services—from project management, design, fabrication, and manufacturing to installation, testing, commissioning, and ongoing maintenance.
Our expertise covers the production of sterile salts, corticosteroids, opiate alkaloids, Denatonium, biologics, bio-conjugates, and other critical medical applications essential to the global pharmaceutical sector.
We have extensive experience in EPC, Design and Build, and turnkey solutions, managing specialised equipment such as fast fill lines, finishing units, GMP production facilities, agitators, cappers, blister packers, bulk storage, blowers, boilers, and more. This encompasses new installations, relocations, and the complete setup of production units.
The global pharmaceutical market has grown significantly, reaching approximately 1.27 trillion U.S. dollars by the end of 2020, marking a substantial increase from 2001. Investments in medicines and vaccines have driven remarkable advancements in global health outcomes, with ongoing scientific investments poised to further enhance disease eradication efforts.
In the UK, the pharmaceutical sector employs around 63,000 individuals and contributes approximately £21 billion to the economy. With strong investment from leading firms and a thriving ecosystem of science parks supporting numerous startups, the UK pharmaceutical industry is forecasted to grow by 19.3% to £25 billion by 2023.